title: Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic.
abstract: Certain randomized, placebo-controlled trials of oral supplementation with B. infantis 35624 have demonstrated the amelioration of symptoms of irritable bowel syndrome. Potential GI colonization by B. infantis 35624 or effects of supplementation on resident GI microbiota may pertain to these clinical observations. In this study, fecal excretion of B. infantis 35624 before, during and after 8 weeks of daily treatment was compared in subjects with IBS who received either the encapsulated oral supplement (n = 39) or placebo (n = 37) and in healthy subjects who received the supplement (n = 41). Secondarily, changes in assessed fecal microbiota and IBS symptoms were determined. Supplementation significantly increased fecal B. infantis 35624 excretion vs. placebo in IBS subjects; excretion in healthy subjects receiving supplement was quantitatively similar. Fecal levels of the probiotic declined and approached baseline once dosing ceased, documenting that colonization is transient. Although supplementation increased numbers of B infantis 35624 within the GI tract, limited changes in 10 other fecal taxa were observed either in healthy subjects or those with IBS. No impact on IBS symptoms was observed. Detection of bacterial DNA in fecal samples suggests that the probiotic is able to survive transit through the GI tract, although strain selective culture techniques were not performed to confirm viability of B. infantis 35624 in the feces. Continuous probiotic administration was necessary to maintain steady-state transit. Given the complex spectrum of GI microbiota, however, monitoring perturbations in selected taxa may not be not a useful indicator of probiotic function.
authors.affiliation: Procter & Gamble, Cincinnati, OH, USA.
authors.forename: Duane
authors.initials: D
authors.lastname: Charbonneau
authors.forename: Roger D
authors.initials: RD
authors.lastname: Gibb
authors.forename: Eamonn M M
authors.initials: EM
authors.lastname: Quigley
mesh_terms: D000328:Adult; D000368:Aged; D001644:Bifidobacterium / Q000302:isolation & purification*; D058448:Biota; D004311:Double-Blind Method; D005243:Feces / Q000382:microbiology*; D005260:Female; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000008:administration & dosage; D019936:Probiotics / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010919:Placebos
keywords: bifidobacterium infantis35624; fecal microbiota; irritable bowel syndrome; polymerase chain reaction; probiotics; symptoms
references.citation: Dig Dis Sci. 2002 Nov;47(11):2615-20
references.pmid: 12452404
references.citation: Dis Colon Rectum. 2008 Dec;51(12):1775-80
references.pmid: 18465170
references.citation: Gastroenterology. 2007 Jul;133(1):24-33
references.pmid: 17631127
references.citation: Curr Pharm Des. 2009;15(13):1403-14
references.pmid: 19442165
references.citation: BMC Gastroenterol. 2009 Dec 17;9:95
references.pmid: 20015409
references.citation: Am J Gastroenterol. 2000 May;95(5):1231-8
references.pmid: 10811333
references.citation: Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57
references.pmid: 17919270
references.citation: Eur J Gastroenterol Hepatol. 2001 Oct;13(10):1143-7
references.pmid: 11711768
references.citation: Dig Liver Dis. 2000 May;32(4):294-301
references.pmid: 11515626
references.citation: J Nutr. 1995 Jun;125(6):1401-12
references.pmid: 7782892
references.citation: Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050
references.pmid: 19277023
references.citation: BMC Gastroenterol. 2009 Feb 16;9:15
references.pmid: 19220890
references.citation: Aliment Pharmacol Ther. 2009 Jan;29(1):97-103
references.pmid: 18785988
references.citation: Neurogastroenterol Motil. 2005 Oct;17(5):687-96
references.pmid: 16185307
references.citation: Am J Gastroenterol. 2006 Jul;101(7):1581-90
references.pmid: 16863564
references.citation: Aliment Pharmacol Ther. 2005 Nov 15;22(10):935-42
references.pmid: 16268967
references.citation: Gastroenterol Clin Biol. 2008 Feb;32(2):147-52
references.pmid: 18387426
references.citation: Aliment Pharmacol Ther. 2011 May;33(10):1123-32
references.pmid: 21418261
references.citation: Gut. 2010 Mar;59(3):325-32
references.pmid: 19091823
references.citation: Gastroenterol Clin North Am. 2011 Mar;40(1):105-19
references.pmid: 21333903
references.citation: Probiotics Antimicrob Proteins. 2011 Mar;3(1):1-7
references.pmid: 22247743
references.citation: Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904
references.pmid: 12656692
references.citation: World J Gastroenterol. 2009 Dec 21;15(47):5936-45
references.pmid: 20014457
references.citation: Aliment Pharmacol Ther. 2007 Aug 1;26(3):463-73
references.pmid: 17635381
references.citation: Lancet. 1998 Oct 10;352(9135):1187-9
references.pmid: 9777836
references.citation: Clin Nutr. 2005 Dec;24(6):925-31
references.pmid: 16051399
references.citation: Aliment Pharmacol Ther. 2010 Jul;32(2):144-58
references.pmid: 20412064
references.citation: BMC Gastroenterol. 2010 Sep 19;10:110
references.pmid: 20849659
references.citation: Microbiologica. 1982 Jul;5(3):185-94
references.pmid: 7121297
references.citation: World J Gastroenterol. 2008 May 7;14(17):2650-61
references.pmid: 18461650
references.citation: Aliment Pharmacol Ther. 2005 Jun 1;21(11):1365-75
references.pmid: 15932367
references.citation: Aliment Pharmacol Ther. 2005 Sep 1;22(5):387-94
references.pmid: 16128676
references.citation: Am J Gastroenterol. 2005 Feb;100(2):373-82
references.pmid: 15667495
references.citation: Res Microbiol. 2001 Oct;152(8):735-41
references.pmid: 11686387
references.citation: Gastroenterology. 2005 Mar;128(3):541-51
references.pmid: 15765388